Comparative efficacy of AAC and ibuprofen versus lasmiditan, ubrogepant, and rimegepant for the acute treatment of episodic migraine in adults: a systematic review and network meta-analysis. [PDF]
Front NeurolMitra A +4 more
europepmc +1 more source
Innovative treatments for migraine: a new era. [PDF]
Ther Adv Neurol DisordPistoia F.
europepmc +1 more source
Lasmiditan: A new promising drug in migraine
Annals of Indian Academy of Neurology, 2021 Sanjay Prakash, Kaushik Rana
doaj +1 more source
Acute migraine treatments in patients above age 65. [PDF]
HeadacheShah T +3 more
europepmc +1 more source
5-Hydroxytryptamine 1F receptor loss reduces renal vasculature and prevents lasmiditan-induced recovery following moderate-severe acute kidney injury in mice. [PDF]
Am J Physiol Renal PhysiolThompson AD +6 more
europepmc +1 more source
Lasmiditan restores mitochondrial quality control mechanisms and accelerates renal recovery after ischemia-reperfusion injury. [PDF]
Biochem Pharmacol, 2023 Hurtado KA, Janda J, Schnellmann RG.
europepmc +1 more source
Real-World Experience of Lasmiditan for the Acute Treatment of Migraine. [PDF]
J Clin NeurolJeong HJ, Lee MJ.
europepmc +1 more source
A Case of Reversible Posterior Leukoencephalopathy Syndrome (PRES) With a History of Migraine and Onset With Initial Visual Aura and Migraine-Like Headache, With a Significant Response to Lasmiditan: A Case Report. [PDF]
Cureus, 2023 Sadamoto Y.
europepmc +1 more source
Emerging pharmacological targets in migraine therapy: CGRP and beyond. [PDF]
Front PharmacolAtraszkiewicz D, Dahiya D.
europepmc +1 more source
Lasmiditan induces mitochondrial biogenesis in primary mouse renal peritubular endothelial cells and augments wound healing and tubular network formation. [PDF]
Am J Physiol Cell PhysiolThompson AD +5 more
europepmc +1 more source